IRulya Therapeutics Financial Statements
NASDAQ: IRLAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
39.88-0.06 (-0.15%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
IRulya Therapeutics revenue and earnings
IRulya Therapeutics reported a net loss of $84.0 million, compared with a loss of $56.8 million a year earlier. Diluted earnings per share came in at -$1.68.
Summary generated from market data by MetaCap's automated system. Methodology
IRulya Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Operating Expenses | 58.07M | 57.28M | 34.62M | 52.02M | 90.32M | 78.89M | 39.17M | 12.12M |
| Research & Development | 35.38M | 18.59M | 9.45M | 25.18M | 60.80M | 61.31M | 30.21M | 10.09M |
| Operating Income | -58.07M | -57.28M | -34.62M | -52.02M | -90.32M | -78.89M | -39.17M | -12.12M |
| Interest Expense | — | — | — | — | — | — | — | 957.00K |
| Other Income (Expense) | 486.00K | -676.00K | -102.00K | -997.00K | -247.00K | 0 | 0 | — |
| Pretax Income | -80.77M | -56.74M | -31.58M | -51.94M | -89.94M | -76.85M | -36.98M | — |
| Income Tax | 3.21M | 87.00K | -197.00K | -284.00K | 0 | 0 | 0 | 0 |
| Net Income | -83.98M | -56.83M | -31.39M | -51.66M | -89.94M | -76.85M | -36.98M | -12.48M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — |
| EPS (Basic) | -1.68 | -1.31 | -0.84 | -1.54 | -3.03 | -2.63 | -1.94 | -3.71 |
| EPS (Diluted) | -1.68 | -1.31 | -0.84 | -1.54 | -3.03 | -2.63 | -1.94 | -3.71 |
| Shares Outstanding (Basic) | 50.10M | 43.26M | 37.24M | 33.50M | 29.72M | 29.18M | 19.03M | 3.36M |
| Shares Outstanding (Diluted) | 50.10M | 43.26M | 37.24M | 33.50M | 29.72M | 29.18M | 19.03M | 3.36M |
| EBITDA | -57.93M | -57.10M | -34.30M | -51.81M | -89.97M | -78.56M | -38.98M | -12.07M |
This table shows 8 annual periods of IRulya Therapeutics's income statement, from FY 2025 back to FY 2018, across 13 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow IRLA's reporting calendar. What is a income statement?